Oncimmune Reels In New Strategy Head And More Capital
Executive Summary
Oncimmune, the UK specialist in autoantibody-based tests for early cancer detection, has bullked up its human and financial resources with the appointment of a chief medical and strategy officer, and the closing of an investment tranche from its Chinese partner.
You may also be interested in...
Oncimmune Expands Application Of Liquid Biopsy Auto-Antibody Technology
The company’s liquid biopsy test business is complemented by a patient-stratification service for pharmaceutical companies.
Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?
While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.
Oncimmune Kicks Off 2018 With China Pact For Lung Cancer Test
Oncimmune's commercialization of its early cancer diagnostic technology continues to gather pace as the firm enlists yet another distribution partner in Asia. The exclusive deal is for China, where the market opportunity for the company's EarlyCDT-Lung test is sizeable. The agreement also includes an equity investment by the Chinese partner in Oncimmune.